EMA News Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–8 of 8 articles
EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
EMA backs datopotamab deruxtecan for advanced lung cancer
Eli Lilly raises 2026 revenue guidance on Mounjaro demand
Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
Top 10 Pharmaceutical Stocks to Buy for June 2026: A B2B Analysis
Navigating Demands for Unvaccinated Donor Blood: A Hospital's Ethical and Operational Challenge
The Demand for Unvaccinated Blood Transfusions: A Growing Concern
EU and US Split on AstraZeneca's Breast Cancer Drug Approval